

## Pharmacy\_Subscriberlist@DCA

---

**From:** Board of Pharmacy <pharmacy.subscriberlist@DCA.CA.GOV>  
**Sent:** Wednesday, September 16, 2015 1:00 PM  
**To:** PHARM-GENERAL@DCALISTS.CA.GOV  
**Cc:** Pharmacy\_Subscriberlist@DCA  
**Subject:** Market Withdrawal - Jubilant Cadista Pharmaceuticals, Inc.

Jubilant Cadista Pharmaceuticals, Inc. is initiating a market withdrawal for all batches in all packaging configurations that are within the expiration date (not yet expired) for Bupropion Hydrochloride Extended Release Tablets USP. The reason for this market withdrawal is the 6-months controlled room temperature stability data from the process validation batches indicate an increasing trend for one of the known degradation products, m-chlorobenzoic acid.

Please immediately check your inventory, quarantine, discontinue distribution of the affected product, and contact your wholesaler for directions.

Bupropion Hydrochloride Extended Release Tablets USP, 100 mg, 60-ct. NDC #: 59746-315-60  
Bupropion Hydrochloride Extended Release Tablets USP, 100 mg, 100-ct. NDC #: 59746-315-01  
Bupropion Hydrochloride Extended Release Tablets USP, 150 mg, 60-ct. NDC #: 59746-316-60  
Bupropion Hydrochloride Extended Release Tablets USP, 150 mg, 100-ct. NDC #: 59746-316-01  
Bupropion Hydrochloride Extended Release Tablets USP, 200 mg, 60-ct. NDC #: 59746-317-60  
Bupropion Hydrochloride Extended Release Tablets USP, 200 mg, 100-ct. NDC #: 59746-317-01